TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07594119: Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures

Sponsor: Rapport Therapeutics Inc. · Phase: PHASE3 · Area: CNS_NEUROLOGY · Target Enrollment: 312 pts

Competing Trials Overlap

9 Active Trials

Excess Burn Exposure

$9,696,896

Rescue Site Savings

+$6,391,136

Unlock Full NCT07594119 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07594119 Rescue Dossier →